Clinical Trial: NCT04129502
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Takeda |
| Information Provided By: | Takeda |
| Last Update Posted: | 2026-10-23 |
Study Overview
Brief Summary
The purpose of this study is to compare effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Participants will be randomly assigned to one of the two treatment groups- TAK-788 group or Platinum-based chemotherapy group.
Participants will receive TAK-788 orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.
Official Title
Conditions
Intervention / Treatment
- Drug: TAK-788
- Drug: Pemetrexed
- Drug: Cisplatin
- Drug: Carboplatin
Other Study ID Numbers
- TAK-788-3001
- NL20191212
- 2019-001845-42
- U1111-1232-6059
- jRCT2071210098
- 2019
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Takeda |
| Information Provided By: | Takeda |
| Last Update Posted: | 2026-10-23 |
Study Overview
Brief Summary
The purpose of this study is to compare effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Participants will be randomly assigned to one of the two treatment groups- TAK-788 group or Platinum-based chemotherapy group.
Participants will receive TAK-788 orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.
Official Title
Conditions
Intervention / Treatment
- Drug: TAK-788
- Drug: Pemetrexed
- Drug: Cisplatin
- Drug: Carboplatin
Other Study ID Numbers
- TAK-788-3001
- NL20191212
- 2019-001845-42
- U1111-1232-6059
- jRCT2071210098
- 2019